All News

Found 183 articles

• Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

  6/6/2023

  Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST).

• AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

  5/31/2023

  AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the formation of a Scientific Advisory Board.

• Exscientia Business Update for First Quarter 2023

  5/24/2023

  Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT.

• Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe

  5/22/2023

  Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition being held May 22-26, 2023, in Brussels, Belgium.

• New Clarivate Biopharma Dealmaking Report Reveals Investment Patterns Set to Impact the Future of Medicine

  5/17/2023

  Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, released its new report, Biopharma Dealmaking in 2023.

• Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023

  5/17/2023

  Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets.

• Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

  5/15/2023

  Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.

• 

  EQRx Cuts More Than Half of Headcount in Strategic Reset

  5/9/2023

  The pharma company will lay off 170 employees and drop all candidates but one, as it seeks to rebuild its business.

• Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors

  5/3/2023

  Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors.

• Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development

  4/19/2023

  Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL.

• Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast

  3/28/2023

  Captor Therapeutics S.A. discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05.

• Exscientia Business and Financial Update for the Full Year 2022

  3/23/2023

  Exscientia plc. Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.

• Exscientia to Report Full Year 2022 Financial Results on March 23, 2023

  3/16/2023

  Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the open of U.S. markets.

• Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR

  3/15/2023

  Exscientia plc (Nasdaq: EXAI) today announced that four abstracts have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.

• Exscientia Announces Expansion of its Precision Oncology Pipeline

  3/14/2023

  Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor.

• Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform

  3/7/2023

  Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Charité – Universitätsmedizin Berlin (Charité) to utilise Exscientia’s AI-driven precision medicine platform in haematological cancers.

• Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

  3/6/2023

  Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent program and corporate developments.

• Exscientia to Present at Upcoming Investor Conferences in March

  2/22/2023

  Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March.

• Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

  2/2/2023

  Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.

• Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023

  1/5/2023

  Rallybio Corporation provided an update on recent accomplishments and announced expected 2023 clinical milestones.